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Summary Airway dehydration and subsequent hyperosmolarity of periciliary fluid are
considered critical events in exercise-induced bronchoconstriction (EIB). It has been
shown that an in vitro hyperosmolar stimulation of basophils and mast cells with
mannitol can induce the release of histamine and leukotrienes. The aim of this study
was to establish if a hyperosmolar challenge could trigger activation of eosinophils to
release chemokines and lipid mediators. Peripheral blood eosinophils were isolated
from seven asthmatic and six non-asthmatic subjects. Hyperosmolar stimulation of
eosinophils with mannitol (0.7M), resulted in a significant increase in LTC4 levels
compared to baseline in both asthmatic (15.274.6 vs. 70.179.5; P ¼ 0:0002) and
control subjects (14.374.0 vs. 55.675.6; P ¼ 0:0001). ECP levels did not increase
significantly above baseline following mannitol stimulation in either group. This study
shows that eosinophils can be activated by a hyperosmolar stimulus. Therefore it
seems reasonable to suggest that eosinophils could contribute to EIB.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
During exercise, the ventilation rate increases,
thus the respiratory tract needs to condition much
larger volumes of air over a much shorter time. This
causes airway dehydration and subsequent exer-
cise-induced bronchoconstriction (EIB) in a large
proportion of asthmatics.1–4 The finding in 1977,1
that inhaling fully humidified air at body conditions
could prevent EIB, demonstrated the importance of
water loss from the airways. Airway dehydration
and the subsequent hyperosmolarity of the peri-
ciliary fluid are considered critical events in
exercise-induced bronchoconstriction.5,6 One hy-
pothesis suggests that the hyperosmolar environ-
ment triggers release of bronchoconstricting
mediators from inflammatory cells.7 It has been
shown that an in vitro hyperosmolar stimulus with
mannitol can induce the release of mediators,
including histamine and leukotrienes, from baso-
phils and mast cells.8–10
The eosinophil is an effector cell in the
inflammed asthmatic airway. Eosinophils release
cytotoxic granules and generate lipid meditors such
as cysteinyl leukotrienes that cause bronchial
epithelial damage and bronchoconstriction, respec-
tively.11,12 Therefore, the aim of this study was to
establish if a hyperosmolar challenge could trigger
activation of eosinophils to release chemokines and
lipid mediators, which could promote bronchocon-
striction and perpetuate inflammation in the
asthmatic airway.
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Methods
Subjects
Seven atopic subjects who met the American
Thoracic Society criteria for mild asthma, and six
non-atopic, non-asthmatic control subjects volun-
teered to participate in this study. Subject char-
acteristics are displayed in Table 1. Atopy was
determined in subjects using a battery of skin prick
test antigens with a positive response defined as a
grade 2+ reaction (erythema 21–30mm, papule 5–
10mm), to at least one antigen. All asthmatic
subjects had episodic symptoms of shortness of
breath, wheeze, cough or chest tightness con-
trolled by use of as required inhaled bronchodilator
therapy. None of the asthmatic subjects had taken
oral or inhaled corticosteroid therapy within the 3
months before the study, and none was taking
theophylline, cromones or leukotriene modifiers.
Approval for this study was obtained from the local
Ethics Committee of James Connolly Memorial
Hospital, and full written informed consent was
obtained from each subject.
Eosinophil purification and stimulation
Peripheral blood (70ml) was collected from each
subject into lithium heparinised tubes, and blood
was diluted with an equal volume of ice cold
phosphate buffered saline (PBS). Isotonic Percoll
(15ml) (density 1.082 g/ml) was layered under
30ml aliquots of blood, and centrifuged at
3000 rpm for 30min at room temperature. Follow-
ing centrifugation, the upper layer containing
mononuclear cells, serum, and Percoll were dis-
carded. The remaining erythrocyte pellet, contain-
ing the polymorphonuclear cells (PMN), was
suspended in PBS containing 2% heat inactivated
fetal calf serum (PBS/FCS). The red cells were then
lysed with reverse osmosis sterile water (40ml for
30 s), and 4 PBS was used to return the cell
suspension to isotonicity. Cell lysis was repeated 2–
3 times. The PMN were incubated for 1 h at 41C in
5ml PBS/FCS with anti-CD16 immunomagnetic
microbeads (Miltenyi Biotec, England). Following
this, PMN were then layered onto a magnetic cell
separation column type CS (Miltenyi Biotec, Eng-
land), and unlabelled eosinophils were eluted with
45ml of ice cold PBS/FCS. This procedure resulted
in total yields of 6–12 million viable eosinophils as
counted with a modified Neubauer hemocytometer
(Knittel, Glaser, Germany), with a purity of 98–99%
as assessed by Diff-Quik staining and a viability of
99% as assessed by Trypan Blue. Purified eosinophils
were suspended at 1 106 cells/ml in RPMI 1640
culture medium supplemented with penicillin
(103 U/ml), streptomycin (10mg/ml), L-glutamine
(2mM), and 10% FCS. Cells were stimulated with
calcium ionophore (A23187) 2.5 mM and hyperosmo-
lar mannitol 0.7M for 15min, in a humidified
incubator at 371C with 5% CO2. Stimulation was
then terminated by addition of ice-cold methanol
to each well, and supernatants were removed and
stored at –201C until analysis.
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Table 1 Subject characteristics of eosinophil donors.
Asthmatic subjects Age (years) Sex Atopy/Allergen Therapy
1 29 F HDM 2+ S (prn)
2 25 M HDM 3+ S (prn)
3 21 M HDM 3+ S (prn)
4 19 F HDM 2+ S (prn)
5 17 M HDM 3+, GRASS 2+ S (prn)
6 35 F HDM 2+, GRASS 2+ S (prn)
7 51 M HDM 3+, GRASS 3+ S (prn)
Non-asthmatic subjects Age (years) Sex Atopy/Allergen Therapy
1 22 F
2 23 M
3 33 F
4 24 M
5 24 F
6 45 F
Hdm = house dust mite, Grass = grass mix, S = salbutamol, prn = taken as required.
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Analysis of mediators
Leukotriene C4 (LTC4)
LTC4 was measured with a commercially available
enzyme-immunoassay kit (Cayman Chemical Co,
Ann Arbor, MI, USA). The lower limit of detection of
this assay is 7.8 pg/ml, and at 50% maximum
binding the antibody shows a cross-reactivity of
48% with LTD5, 45% with LTD4, 28% with N-acetyl
LTE4, 7% with LTE5, and less than 0.01% with other
eicosanoids.
Eosinophil cationic protein (ECP)
ECP was measured with a commercially available
radio-immunoassay kit (Pharmacia-Upjohn AC, Up-
psala, Sweden). The lower limit of detection of this
assay is 2 mg/l, and at 50% maximum binding the
antibody shows a cross-reactivity of o0.06% with
EPX.
Data analysis
Normally distributed data (as assessed by Kolmo-
gorov-Smirnov) are expressed as group mean7 SE.
Differences between groups were assessed using a
one-way analysis of variance and students t-test.
Results were considered significant if Po0:05: The
statistical calculations were controlled by the use
of a validated statistical software package for
personal computers (Graph Pad Prism Inc, San
Diego, CA, USA).
Results
Baseline levels of LTC4 and ECP did not differ
between the asthmatic or control group. Following
stimulation with calcium ionophore, a significant
increase in LTC4 levels above baseline was seen in
both asthmatic (P ¼ 0:0005) and control subjects
(P ¼ 0:03) (Fig. 1a). Levels of ECP did not sig-
nificantly increase from baseline in either asth-
matic (P ¼ 0:41) or control subjects (P ¼ 0:71)
following ionophore stimulation (Fig. 1b). Hyper-
osmolar stimulation of eosinophils with mannitol,
resulted in a significant increase in LTC4 levels
compared to baseline in both asthmatic (15.274.6
vs. 70.179.5; P ¼ 0:0002) and control subjects
(14.374.0 vs. 55.675.6; P ¼ 0:0001) (Fig. 1a). In
contrast, ECP levels did not increase significantly
above baseline following mannitol stimulation in
either the asthmatic (P ¼ 0:36) or control subjects
(P ¼ 0:30) (Fig. 1b).
Discussion
This study shows that hyperosmolar stimulation of
eosinophils resulted in the release of LTC4. In the
trachea the osmolarity of secretions has been
demonstrated to be 360mOsm/kg H2O.
9 Anderson
et al.13 suggested that after exercise bronchial
secretions may result in an osmolarity of
900mOsm/kg H2O. Basophils and lung mast cells
are activated by hyperosmolar mannitol, maximal
histamine release from basophils was achieved at
1050mOsm/kg, whereas mast cells released
maximally at 700–750mOsm/kg. In the current
study, purified eosinophils were stimulated with
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Fig. 1 (A) Mean7SE leukotriene C4 (LTC4) levels (pg/ml)
from eosinophils isolated from asthmatic (open bars) and
non-asthmatic control subjects (filled bars). Following a
hyperosmolar stimulation of eosinophils with mannitol, a
significant increase in LTC4 is seen compared to unstimu-
lated eosinophils, in both asthmatic (P ¼ 0:0002) and
control subjects (P ¼ 0:0001). There is no significant
difference between asthmatic and control subjects, in
LTC4 levels from unstimulated eosinophils (P=0.9), and
from mannitol stimulated eosinophils (P ¼ 0:2). (B)
Mean7SE eosinophil cationic protein (ECP) levels (mg/l)
from eosinophils isolated from asthmatic (open bars) and
non-asthmatic control subjects (filled bars). Following a
hyperosmolar stimulation of eosinophils with mannitol,
no significant increase in ECP levels was detected
compared to unstimulated eosinophils, in both asthmatic
(P ¼ 0:4) and control subjects (P ¼ 0:3).
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hyperosmolar (0.7 M) mannitol (equivalent to ap-
prox. 950mOsm/kg) to try to mimic the conditions
in vitro, that may occur in vivo after exercise.
Epithelial cells have previously been stimulated
with similar molar concentrations of mannitol,
without any evidence of cytotoxicity to cells as
assessed by LDH expression.14 Cells were stimu-
lated for 15min to avoid hyperosmolar-induced
cytotoxicity, which might have occurred with a
longer incubation period. We found that LTC4
generation following hyperosmolar stimulation
was not a unique characteristic of eosinophils
from asthmatic subjects only. Hodges et al.15
previously showed that eosinophils from asthmatic
subjects, when stimulated with calcium ionophore,
have a decreased capacity for LTC4 synthesis
compared with eosinophils of similar density
isolated from normal subjects. It is generally
accepted that the magnitude of EIB is strongly
correlated with the underlying degree of airway
hyperresponsiveness.16 Therefore, it is tempting to
speculate that the underlying airway hyperrespon-
siveness of asthmatic subjects causes them to be
more ‘‘primed’’ to the effects of LTC4 and other
bronchoconstricting mediators, compared to nor-
mal subjects.
One of the consequences of airway inflammation
in asthma is thought to be desquamation of airway
epithelial cells resulting from the action of inflam-
matory mediators such as eosinophil granule
proteins.17 However, it has previously been sug-
gested that ECP is not related to bronchial
hyperreactivity.18 It is possible that we may have
missed the peak effect of ECP release at 15min, as
it has previously been shown that eosinophil
degranulation peaks after 10min incubation with
calcium ionophore.19 Moreover, Takafugi and col-
leagues demonstrated that neither TNF or GM-CSF
could induce ECP release from human eosinophils,20
and eosinophils from atopic asthmatics did not
release ECP after incubation with specific allergen
or with anti-IgE monoclonal antibodies.21
To the best of our knowledge purified eosinophils
have not been subjected to a hyperosmolar
challenge. This is surprising given that eosinophils
are one of the primary sources of the potent
bronchoconstricting cysteinyl-leukotrienes.22 To-
gias and colleagues have shown increased LTC4 in
nasal lavage following a cold dry air nasal chal-
lenge.10 The osmolarity of the nasal secretions was
increased in those subjects sensitive to cold dry air.
Nasal lavage collected from 15 healthy volunteers
following a nasal challenge with hyperosmolar
mannitol (869mOsm/kg) contained significantly
higher quantities, as compared to baseline, of
immunoreactive leukotrienes LTD4/LTE4.
23 In vitro
work with hyperosmolar stimulated basophils and
mast cells have yielded confounding results. Fin-
dlay et al. investigated basophil cell supernatants
for production of cysteinyl leukotrienes following
stimulation with hyperosmolar solutions, but could
not document an increase in the cysteinyl leuko-
triene production.8 It should be noted however,
that guinea pig ileal contractions were used to
assay the cysteinyl leukotrienes with a compara-
tively poor sensitivity compared to present day
methodology. A study using the more sensitive
radioimmunoassay did detect a non-significant
doubling in the production of LTC4/LTD4 from
isolated basophils stimulated with hyperosmolar
mannitol.24 In the same study, the investigators did
not however observe an increase in LTC4/LTD4 from
human lung mast cells following hyperosmolar
challenge. Cells from chopped nasal polyps contain-
ing epithelial and mononuclear cells as well as
eosinophils and neutrophils were stimulated to
produce increased levels of 15-hydroxyeicosatetra-
noic acid and leukotriene B4 following incubation
with hyperosmolar buffer solution.14 Unfortunately,
levels of LTC4 were not assayed.
In summary, our study demonstrates that
eosinophils can be activated by a hyperosmolar
stimulus to release LTC4. Therefore it seems
reasonable to suggest that eosinophils could con-
tribute to EIB.
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